Medication Monitor



Generic Name (Trade Name—Company)
Notes
June 12, 2019

Midazolam

(Nayzilam—UCB)
Nasal spray now approved to treat intermittent, stereotypic episodes of frequent seizure activity

UCB announced FDA approval of midazolam nasal spray, a benzodiazepine indicated for acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy who are aged 12 years and older.    

The agent is a Schedule IV Controlled Substance that can be administered by a non–health care professional in patients actively seizing when and where a seizure cluster occurs. The nasal spray is designed as a single-use treatment that can be carried with a patient. 

Concomitant use of benzodiazepines (including midazolam) and opioids may result in profound sedation, respiratory depression, coma, and death. See the prescribing information for more information.